Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Meglumine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 9/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP12 | P39900 | 1/20 | 0.35 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1857817 | 0.87 | FFAR1 (0.50) | FFAR1FFAR4PTGESMMP2MMP12 | |
| SCHEMBL1853713 | 0.82 | FFAR1 (0.49) | FFAR1FFAR4PTGESMMP2MMP12 | |
| SCHEMBL1853166 | 0.82 | FFAR1 (0.49) | FFAR1FFAR4PTGESMMP2MMP12 | |
| SCHEMBL1855022 | 0.82 | FFAR1 (0.49) | FFAR1FFAR4PTGESMMP2MMP12 | |
| SCHEMBL4669841 | 0.78 | PTGES (0.47) | FFAR1FFAR4PTGESMMP2MMP12 | |
| Meglumine SCHEMBL6421775 | 0.77 | FFAR1 (0.39) | FFAR1FFAR4PTGESMMP2MMP12 | |
| SCHEMBL1856989 | 0.77 | FFAR1 (0.44) | FFAR1FFAR4PTGESMMP2MMP12 | |
| SCHEMBL1851186 | 0.77 | FFAR1 (0.62) | FFAR1FFAR4MMP2MMP12TNK2 | |
| Meglumine SCHEMBL1858380 | 0.74 | TMEM97 (0.42) | — | |
| SCHEMBL1856990 | 0.74 | FFAR1 (0.43) | FFAR1FFAR4PTGESMMP2MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124656-A1 | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps) | APPLIED RESEARCH SYSTEMS ARS (NL) | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124656-A1 | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps) | PTPRS, PTPA, PTPMT1 | FFAR1 619/4885FFAR4 968/4885PTGES 1550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.